SI-BONE, Inc. Stock 12‑Month Price Target Raised to $25.78, Implies 27% Upside
Analysts raised SI-BONE, Inc.'s 12-month price target from $25.44 to $25.78, suggesting 27% upside. All 9 analysts maintain a 'Buy' rating. The forecasts range from $23 to $32 per share, based on November 2 closing price.
How this was made
The 30-second read
Why it matters
Analyst consensus remains a Buy, reinforcing the positive outlook.
Market read
Analyst target raise may prompt short‑term buying interest.
What to watch
No new product or regulatory news accompanies the target change.
Background
SI‑BONE is a medical device company focused on spinal fusion technologies.
Ticker impact
Analysts raised the average 12‑month price target for SI‑BONE to $25.78, implying ~27% upside.
potential upside as traders price in the higher target
Target raise is a fresh analyst action that signals improved expectations.
Market effects
May lift sentiment in the orthopedic device sector.
Limited to U.S. biotech/medical device investors.
Minimal global impact.
Counterpoint
Target raises could be premature if upcoming earnings miss expectations.
Key entities
- CompanySI‑BONE, Inc.
Medical device manufacturer.
